{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:38:55Z","timestamp":1789133935026,"version":"build-2803163510"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Bone mineral density (BMD) monitoring, primarily relying on dual-energy X-ray absorptiometry (DEXA), remains inaccessible in resource-limited regions, making it difficult to promptly address bone loss in people with HIV (PWH) on long-term ART-containing TDF regimens and assess the prevalence of bone loss. Our objective is to identify the frequency of PWH experiencing bone loss after long-term ART with a TDF regimen and to develop a predictive model of HIV-infected high-risk populations containing TDF long-time ART, for providing more appropriate ART regimens for PWH in clinical practice, particularly in resource-limited settings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Our study retrospectively screened PWH under long-term follow-up at Peking Union Medical College Hospital (PUMCH) from January 2000 to August 2024. These individuals were either treatment-naive or treatment-experienced and had been on containing TDF ART regimen for over 5\u00a0years. BMD was assessed using DEXA every 1\u20132\u00a0years in this center. We selected predictive factors utilizing machine learning methods, including Random Forest, XGBoost, LASSO regression, and logistic regression. The results were visualized using a nomogram.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Our study enrolled a total of 232 PWH who have contained TDF ART regimens for more than 5\u00a0years. Twenty-five percent (58\/232) of the patients experienced bone loss, primarily including osteopenia and osteoporosis. Further results showed that the LASSO regression model was the most suitable for the current dataset, based on a comparison of LASSO regression, Random Forest, XGBoost, and logistic regression models including age, gender, LPV\/r, baseline CD4+ T count, baseline VL, baseline body weight, treatment-na\u00efve TDF, ART duration, percentage of CD38+CD8+T, percentage of HLA-DR+CD8<jats:sup>+<\/jats:sup> T, and CD4+\/CD8+ ratio, with AUC values of 0.615, 0.507, 0.593, and 0.588, respectively. We identified age, gender, and LPV\/r as the most relevant predictive factors associated with bone loss based on LASSO regression. Then the results were visualized and plotted in a nomogram.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our study quantified the frequency and established a nomogram based on the LASSO regression model to predict bone loss in PWH on long-term containing TDF ART. The nomogram guides identifying individuals at high risk of bone loss due to prolonged TDF exposure. Clinicians can leverage the predicted risk to design personalized ART regimens at the initiation of therapy or to switch from TDF-containing to TDF-free regimens during treatment. This approach aims to reduce the incidence of bone loss, particularly in resource-limited settings.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1516013","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T14:16:05Z","timestamp":1743776165000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Bone loss in young adults with HIV following antiretroviral therapy containing tenofovir disoproxil fumarate regimen using machine learning"],"prefix":"10.3389","volume":"16","author":[{"given":"Ling","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leidan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyuan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fada","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuping","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.3390\/microorganisms11102426","article-title":"HIV and an ageing population-what are the medical, psychosocial, and palliative care challenges in healthcare provisions","volume":"11","author":"Ahmed","year":"2023","journal-title":"Microorganisms"},{"key":"B2","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1186\/s12879-021-06263-9","article-title":"Increased risk factors associated with lower BMD in antiretroviral-therapy-naive HIV-infected adult male","volume":"21","author":"Atencio","year":"2021","journal-title":"BMC Infect. Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s00223-022-00946-4","article-title":"Osteoporosis and HIV infection","volume":"110","author":"Biver","year":"2022","journal-title":"Calcif. Tissue Int."},{"key":"B4","doi-asserted-by":"publisher","first-page":"4522","DOI":"10.1210\/jc.2007-1660","article-title":"CLINICAL Review #: low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis","volume":"92","author":"Bolland","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B5","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1097\/QAI.0b013e3181adce44","article-title":"Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen","volume":"51","author":"Brown","year":"2009","journal-title":"J. Acquir Immune Defic. Syndr."},{"key":"B6","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1097\/QAD.0b013e3282f423dd","article-title":"Reduced bone mineral density in HIV-infected patients: prevalence and associated factors","volume":"22","author":"Cazanave","year":"2008","journal-title":"AIDS"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e0196201","DOI":"10.1371\/journal.pone.0196201","article-title":"Prevalence of and risk factors for low bone mineral density in Spanish treated HIV-infected patients","volume":"13","author":"Cervero","year":"2018","journal-title":"PLoS One"},{"key":"B8","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.ecl.2014.05.001","article-title":"Osteoporosis and fracture risk associated with HIV infection and treatment","volume":"43","author":"Compston","year":"2014","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"B9","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/joim.12520","article-title":"HIV infection and bone disease","volume":"280","author":"Compston","year":"2016","journal-title":"J. Intern Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","article-title":"Clinician's guide to prevention and treatment of osteoporosis","volume":"25","author":"Cosman","year":"2014","journal-title":"Osteoporos. Int."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1093\/cid\/ciw120","article-title":"Analysis of non-AIDS-defining events in HIV controllers","volume":"62","author":"Dominguez-Molina","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1097\/QAD.0000000000000363","article-title":"Osteoporosis and fractures in HIV\/hepatitis C virus coinfection: a systematic review and meta-analysis","volume":"28","author":"Dong","year":"2014","journal-title":"AIDS"},{"key":"B13","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1093\/qjmed\/hcn022","article-title":"DXA scanning in clinical practice","volume":"101","author":"El Maghraoui","year":"2008","journal-title":"QJM"},{"key":"B14","doi-asserted-by":"publisher","first-page":"8880786","DOI":"10.1155\/2020\/8880786","article-title":"Risk assessment of hip fracture based on machine learning","volume":"2020","author":"Galassi","year":"2020","journal-title":"Appl. Bionics Biomech."},{"key":"B15","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jot.2021.04.002","article-title":"Changes in trabecular bone score and bone mineral density in Chinese HIV-Infected individuals after one year of antiretroviral therapy","volume":"29","author":"Guan","year":"2021","journal-title":"J. Orthop. Transl."},{"key":"B16","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00198-020-05584-w","article-title":"Longitudinal change in bone mineral density among Chinese individuals with HIV after initiation of antiretroviral therapy","volume":"32","author":"Guo","year":"2021","journal-title":"Osteoporos. Int."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e0230368","DOI":"10.1371\/journal.pone.0230368","article-title":"Bone mineral density changes among people living with HIV who have started with TDF-containing regimen: a five-year prospective study","volume":"15","author":"Han","year":"2020","journal-title":"PLoS One"},{"key":"B18","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/S2055-6640(20)30248-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?","volume":"4","author":"Hill","year":"2018","journal-title":"J. Virus Erad."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1002\/jbmr.1861","article-title":"Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: the SMART body composition substudy","volume":"28","author":"Hoy","year":"2013","journal-title":"J. Bone Min. Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/jbmr.3183","article-title":"Immediate initiation of antiretroviral therapy for HIV infection accelerates bone loss relative to deferring therapy: findings from the START bone mineral density substudy, a randomized trial","volume":"32","author":"Hoy","year":"2017","journal-title":"J. Bone Min. Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e32661","DOI":"10.7759\/cureus.32661","article-title":"HIV-associated conditions in older adults","volume":"14","author":"Jaqua","year":"2022","journal-title":"Cureus"},{"key":"B22","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.bone.2009.01.373","article-title":"FRAX and its applications to clinical practice","volume":"44","author":"Kanis","year":"2009","journal-title":"Bone"},{"key":"B23","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/infdis\/jiu499","article-title":"Low bone mineral density in patients with well-suppressed HIV infection: association with body weight, smoking, and prior advanced HIV disease","volume":"211","author":"Kooij","year":"2015","journal-title":"J. Infect. Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/QAI.0b013e318134257a","article-title":"HIV-infected adults with a CD4 cell count greater than 500 cells\/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population","volume":"46","author":"Lewden","year":"2007","journal-title":"J. Acquir Immune Defic. Syndr."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.bone.2008.08.106","article-title":"International society for clinical densitometry 2007 adult and pediatric official positions","volume":"43","author":"Lewiecki","year":"2008","journal-title":"Bone"},{"key":"B26","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1002\/oby.21371","article-title":"Isocaloric fructose restriction and metabolic improvement in children with obesity and metabolic syndrome","volume":"24","author":"Lustig","year":"2016","journal-title":"Obes. (Silver Spring)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/S0140-6736(14)60164-1","article-title":"HIV infection: epidemiology, pathogenesis, treatment, and prevention","volume":"384","author":"Maartens","year":"2014","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e655","DOI":"10.1016\/S2352-3018(19)30195-X","article-title":"Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial","volume":"6","author":"Maggiolo","year":"2019","journal-title":"Lancet HIV"},{"key":"B29","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1086\/656412","article-title":"Bone disease in HIV infection: a practical review and recommendations for HIV care providers","volume":"51","author":"McComsey","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1097\/QAI.0000000000002958","article-title":"Prevalence and risk factors of low bone mineral density in HIV\/AIDS patients: a Chinese cross-sectional study","volume":"90","author":"Meng","year":"2022","journal-title":"J. Acquir Immune Defic. Syndr."},{"key":"B31","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.eimc.2017.03.010","article-title":"Executive summary of the consensus document on osteoporosis in HIV-infected individuals","volume":"36","author":"Negredo","year":"2018","journal-title":"Enferm. Infecc. Microbiol. Clin. Engl. Ed."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s00198-008-0588-0","article-title":"Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks","volume":"19","author":"Nguyen","year":"2008","journal-title":"Osteoporos. Int."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1016\/S2352-3018(17)30031-0","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study","volume":"4","author":"Orkin","year":"2017","journal-title":"Lancet HIV"},{"key":"B34","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.medmal.2018.02.009","article-title":"Prevalence and risk factors for low bone mineral density in antiretroviral therapy-naive HIV-infected young men","volume":"48","author":"Paccou","year":"2018","journal-title":"Med. Mal. Infect."},{"key":"B35","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3109\/00365548.2014.968610","article-title":"Bone mineral density changes after 2 years of ARV treatment, compared to naive HIV-1-infected patients not on HAART","volume":"47","author":"Rey","year":"2015","journal-title":"Infect. Dis. (Lond)."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e81355","DOI":"10.1371\/journal.pone.0081355","article-title":"Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada","volume":"8","author":"Samji","year":"2013","journal-title":"PLoS One"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s40265-020-01379-9","article-title":"HIV-1 integrase inhibitors: a comparative review of efficacy and safety","volume":"80","author":"Scarsi","year":"2020","journal-title":"Drugs"},{"key":"B38","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11657-024-01413-3","article-title":"Prevalence and associated factors of low bone mineral density in people living with HIV: a cross-sectional study","volume":"19","author":"Shao","year":"2024","journal-title":"Arch. Osteoporos."},{"key":"B39","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1093\/cid\/ciab874","article-title":"Human immunodeficiency virus (HIV) and menopause are independently associated with lower bone mineral density: results from the women's interagency HIV study","volume":"75","author":"Sharma","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/QAI.0000000000002207","article-title":"Management of osteoporosis in patients living with HIV-A systematic review and meta-analysis","volume":"83","author":"Starup-Linde","year":"2020","journal-title":"J. Acquir Immune Defic. Syndr."},{"key":"B41","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s12879-019-3871-0","article-title":"HIV-1 drug resistance testing is essential for heavily-treated patients switching from first-to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon","volume":"19","author":"Takou","year":"2019","journal-title":"BMC Infect. Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/COH.0000000000000780","article-title":"Gender and sex considerations in HIV and bone health","volume":"18","author":"Tang","year":"2023","journal-title":"Curr. Opin. HIV AIDS"},{"key":"B43","doi-asserted-by":"publisher","first-page":"20504","DOI":"10.7448\/IAS.19.1.20504","article-title":"Choice of antiretroviral drugs for continued treatment scale-up in a public health approach: what more do we need to know?","volume":"19","author":"Vitoria","year":"2016","journal-title":"J. Int. AIDS Soc."},{"key":"B44","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12879-021-05802-8","article-title":"Pharmacodynamics of efavirenz 400 mg in treatment-na\u00efve Chinese HIV-infected patients in a prospective cohort study","volume":"21","author":"Xu","year":"2021","journal-title":"BMC Infect. Dis."},{"key":"B45","first-page":"367","article-title":"Clinical study of 400mg efavirenz treatment in newly diagnosed patients with HIV\/AIDS","volume":"37","author":"Yang","year":"2024","journal-title":"Pak J. Pharm. Sci."},{"key":"B46","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/COH.0000000000000273","article-title":"How to predict the risk of fracture in HIV?","volume":"11","author":"Yin","year":"2016","journal-title":"Curr. Opin. HIV AIDS"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1516013\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T14:16:17Z","timestamp":1743776177000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1516013\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":46,"alternative-id":["10.3389\/fphar.2025.1516013"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1516013","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,4]]},"article-number":"1516013"}}